Lantheus seeks FDA OK for prostate PET imaging agent

By AuntMinnie.com staff writers

September 30, 2020 -- Lantheus Medical Imaging submitted a new drug application to the U.S. Food and Drug Administration (FDA) for its PyL (F-18 DCFPyL) radiopharmaceutical.

PyL is a prostate specific membrane antigen-targeted small-molecule PET radiopharmaceutical that aims to provide a view of prostate cancer. Lantheus is requesting priority review of PyL, which may shorten the FDA's review time to six months until acceptance. Typically, the review takes 10 months.

If you like this content, please share it with a colleague!